Robert E. Jordan

8.1k total citations · 1 hit paper
109 papers, 6.4k citations indexed

About

Robert E. Jordan is a scholar working on Hematology, Surgery and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Robert E. Jordan has authored 109 papers receiving a total of 6.4k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Hematology, 29 papers in Surgery and 23 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Robert E. Jordan's work include Platelet Disorders and Treatments (26 papers), Monoclonal and Polyclonal Antibodies Research (22 papers) and Heparin-Induced Thrombocytopenia and Thrombosis (18 papers). Robert E. Jordan is often cited by papers focused on Platelet Disorders and Treatments (26 papers), Monoclonal and Polyclonal Antibodies Research (22 papers) and Heparin-Induced Thrombocytopenia and Thrombosis (18 papers). Robert E. Jordan collaborates with scholars based in United States, Canada and Belgium. Robert E. Jordan's co-authors include R. J. Dwayne Miller, Jason R. Dwyer, Bradley J. Siwick, Randall J. Brezski, Robert Rosenberg, G.M. Oosta, Barry S. Coller, R D Rosenberg, Harlan F. Weisman and Mary Ann Mascelli and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Physical Review Letters.

In The Last Decade

Robert E. Jordan

108 papers receiving 6.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

An Atomic-Level View of Melting Using Femtosecond Electron Diffraction

2003 674 citations Robert E. Jordan, R. J. Dwayne Miller et al. profile →

Peers

Countries citing papers authored by Robert E. Jordan

Since Specialization

Citations

This map shows the geographic impact of Robert E. Jordan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert E. Jordan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert E. Jordan more than expected).

Fields of papers citing papers by Robert E. Jordan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert E. Jordan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert E. Jordan. The network helps show where Robert E. Jordan may publish in the future.

Co-authorship network of co-authors of Robert E. Jordan

This figure shows the co-authorship network connecting the top 25 collaborators of Robert E. Jordan. A scholar is included among the top collaborators of Robert E. Jordan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert E. Jordan. Robert E. Jordan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Proteolytic single hinge cleavage of pertuzumab impairs its Fc effector function and antitumor activity in vitro and in vivo 2018 ·Breast Cancer Research ·(unknown), Xuejun Fan, Robert E. Jordan, Ningyan Zhang, Zhiqiang An	17
2	Proteolytic Cleavage and Loss of Function of Biologic Agents That Neutralize Tumor Necrosis Factor in the Mucosa of Patients With Inflammatory Bowel Disease 2015 ·Gastroenterology ·Paolo Biancheri, Randall J. Brezski, Antonio Di Sabatino, Allison R. Greenplate, (unknown), Gino Roberto Corazza, Klaartje Kok, L. Rovedatti, Anna Vossenkämper, (unknown), Susanne A. Snoek, Séverine Vermeire, Paul Rutgeerts, Robert E. Jordan, Thomas T. MacDonald	104
3	An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions 2015 ·mAbs ·Michelle Kinder, Allison R. Greenplate, William R. Strohl, Robert E. Jordan, Randall J. Brezski	34
4	Galactosylation variations in marketed therapeutic antibodies 2012 ·mAbs ·T. Shantha Raju, Robert E. Jordan	98
5	The in vitro resistance of IgG2 to proteolytic attack concurs with a comparative paucity of autoantibodies against peptide analogs of the IgG2 hinge 2011 ·mAbs ·Randall J. Brezski, (unknown), Brandy Strake, Robert E. Jordan	35
6	Cleavage of IgGs by proteases associated with invasive diseases 2010 ·mAbs ·Randall J. Brezski, Robert E. Jordan	117
7	Human Anti-IgG1 Hinge Autoantibodies Reconstitute the Effector Functions of Proteolytically Inactivated IgGs 2008 ·The Journal of Immunology ·Randall J. Brezski, Jennifer L. Luongo, (unknown), Mary Ryan, Degang Zhong, Susan H. Tam, (unknown), Marian Kruszynski, Brian Whitaker, David Knight, Robert E. Jordan	38
8	Femtosecond electron pulse characterization using laser ponderomotive scattering 2006 ·Optics Letters ·Christoph T. Hebeisen, Ralph Ernstorfer, Maher Harb, Thibault Dartigalongue, Robert E. Jordan, R. J. Dwayne Miller	58
9	Effects of abciximab on the acute pathology of blood vessels after arterial stenting in nonhuman primates 2002 ·Journal of the American College of Cardiology ·Tullio Palmerini, Mark Nedelman, L E Scudder, Marian T. Nakada, Robert E. Jordan, Susan S. Smyth, Ronald E. Gordon, John T. Fallon, Barry S. Coller	25
10	Abciximab Pharmacodynamics Are Unaffected by Antecedent Therapy with Other GPIIb/IIIa Antagonists in Non-Human Primates 2002 ·Journal of Thrombosis and Thrombolysis ·Marian T. Nakada, (unknown), Susan H. Tam, Mark Nedelman, Robert E. Jordan, Dean J. Kereiakes	4
11	Effects of 2 Different Anti–Tumor Necrosis Factor–α Agents in a Primate Model of Subcutaneous Abscess Formation 2002 ·The Journal of Infectious Diseases ·(unknown), Floyd E. Fox, (unknown), Amy S. Rosenberg, Robert E. Jordan, David J. Shealy, Carrie Wagner	11
12	Therapeutic heparin concentrations augment platelet reactivity: Implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab 2000 ·American Heart Journal ·Mary Ann Mascelli, Neal S. Kleiman, Stanley J. Marciniak, Lakshmi Damaraju, Harlan F. Weisman, Robert E. Jordan	34
13	Inhibition of angiogenesis and tumor growth by murine 7E3, the parent antibodyof c7E3 Fab (abciximab; ReoProTM) 1999 ·Angiogenesis ·Judith A. Varner, Marian T. Nakada, Robert E. Jordan, Barry S. Coller	40
14	Abciximab inhibits release of platelet granule constituents 1998 ·Journal of the American College of Cardiology ·Mary Ann Mascelli, Stanley J. Marciniak, Ellen T. Lance, Robert E. Jordan	2
15	Synergy of abciximab and ticiopidine in patients undergoing intracoronary stenting 1998 ·Journal of the American College of Cardiology ·Neil Kleiman, (unknown), Ellen T. Lance, (unknown), (unknown), John C. Higginbotham, (unknown), Mark B. Effron, (unknown), Robert E. Jordan	1
16	Abciximab (ReoPro, Chimeric 7E3 Fab) Demonstrates Equivalent Affinity and Functional Blockade of Glycoprotein IIb/IIIa and α _v β ₃ Integrins 1998 ·Circulation ·Susan H. Tam, (unknown), Robert E. Jordan, Marian T. Nakada	219
17	Rapid assessment of platelet inhibition using a modified whole blood aggregometer (aggrestat™) in PTCA patients receiving ReoPro™ 1996 ·Journal of the American College of Cardiology ·Mary Ann Mascelli, Ellen T. Lance, (unknown), Harlan F. Weisman, (unknown), Robert E. Jordan	3
18	Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris. 1990 ·Journal of Clinical Investigation ·Herman K. Gold, Lawrence W. Gimple, Tsunehiro Yasuda, Robert C. Leinbach, Wendy Werner, Robert E. Holt, Robert E. Jordan, Harvey J. Berger, D Collen, Barry S. Coller	135
19	Antithrombin inactivation by neutrophil elastase requires heparin 1989 ·The American Journal of Medicine ·Robert E. Jordan, Richard M. Nelson, (unknown), (unknown), (unknown), Michael A. Fournel	9
20	Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons. 1988 ·PubMed ·Taylor Fb, Emerson Te, Robert E. Jordan, (unknown), (unknown)	96

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact